238 related articles for article (PubMed ID: 27283290)
21. Selective use of vandetanib in the treatment of thyroid cancer.
Fallahi P; Di Bari F; Ferrari SM; Spisni R; Materazzi G; Miccoli P; Benvenga S; Antonelli A
Drug Des Devel Ther; 2015; 9():3459-70. PubMed ID: 26170630
[TBL] [Abstract][Full Text] [Related]
22. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
[TBL] [Abstract][Full Text] [Related]
23. A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.
Bugalho MJ; Domingues R; Borges A
Oncologist; 2009 Nov; 14(11):1083-7. PubMed ID: 19887470
[TBL] [Abstract][Full Text] [Related]
24. RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM; Cavaco BM; Leite V
Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
[TBL] [Abstract][Full Text] [Related]
25. Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.
Carlomagno F; Santoro M
J Chemother; 2004 Nov; 16 Suppl 4():49-51. PubMed ID: 15693160
[TBL] [Abstract][Full Text] [Related]
26. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Moura MM; Cavaco BM; Pinto AE; Leite V
J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
[TBL] [Abstract][Full Text] [Related]
27. Analysis of inherited genetic variants in ret proto-oncogene of Brazilian patients with apparently sporadic medullary thyroid carcinoma.
Guerrero IM; Pessoa CH; Olmedo DB; Pontes ER; Matos LC; Tilli TM; Barcinski MA; Gimba ER
Thyroid; 2006 Jan; 16(1):9-15. PubMed ID: 16487008
[TBL] [Abstract][Full Text] [Related]
28. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
[TBL] [Abstract][Full Text] [Related]
29. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
[TBL] [Abstract][Full Text] [Related]
30. Vandetanib for the treatment of medullary thyroid carcinoma.
Cooper MR; Yi SY; Alghamdi W; Shaheen DJ; Steinberg M
Ann Pharmacother; 2014 Mar; 48(3):387-94. PubMed ID: 24259657
[TBL] [Abstract][Full Text] [Related]
31. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B
Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654
[TBL] [Abstract][Full Text] [Related]
32. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.
Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM
Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075
[TBL] [Abstract][Full Text] [Related]
33. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Vitagliano D; De Falco V; Tamburrino A; Coluzzi S; Troncone G; Chiappetta G; Ciardiello F; Tortora G; Fagin JA; Ryan AJ; Carlomagno F; Santoro M
Endocr Relat Cancer; 2011 Feb; 18(1):1-11. PubMed ID: 20943719
[TBL] [Abstract][Full Text] [Related]
34. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
[TBL] [Abstract][Full Text] [Related]
35. Management of medullary thyroid cancer.
Ball DW
Minerva Endocrinol; 2011 Mar; 36(1):87-98. PubMed ID: 21460789
[TBL] [Abstract][Full Text] [Related]
36. Vandetanib for the treatment of medullary thyroid cancer.
Chau NG; Haddad RI
Clin Cancer Res; 2013 Feb; 19(3):524-9. PubMed ID: 23231950
[TBL] [Abstract][Full Text] [Related]
37. Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.
Starenki D; Park JI
J Clin Endocrinol Metab; 2013 Apr; 98(4):1529-40. PubMed ID: 23509102
[TBL] [Abstract][Full Text] [Related]
38. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
[TBL] [Abstract][Full Text] [Related]
39. Management of hereditary medullary thyroid carcinoma.
Pappa T; Alevizaki M
Endocrine; 2016 Jul; 53(1):7-17. PubMed ID: 26839093
[TBL] [Abstract][Full Text] [Related]
40. [Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer].
Courtier B; Hadoux J
Bull Cancer; 2021 Nov; 108(11):989-991. PubMed ID: 34598787
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
